What to do with TNF failures

Expert Opinion on Drug Safety

Volumn 4, Issue 2, 2005, Pages 149-155

  Keystone, Edward C ^a   Kavanaugh, Arthur ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abatacept; Anti IL 6 receptor; Biologics; Rheumatoid arthritis (RA); Rituximab; Therapeutic targets

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PLACEBO; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL ARTHRITIS; BRONCHITIS; BRONCHOPNEUMONIA; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; INFLUENZA; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; OPEN STUDY; PATHOGENESIS; PHARYNGITIS; PILOT STUDY; PRURITUS; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TRACHEITIS; TREATMENT FAILURE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20944449486     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.2.149     Document Type: Editorial

References (26)

1. BRAUNJ, SIEPER J, VAN DER HEIJDE D: Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. Ann. Rheum Dis. (2003) 62:1023-1024.
2. VAN VOLLENHOVEN RF, KLARESKOG L: Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution; data from the Stockholm tumor necrosis factor alpha followup registry. Arthritis Rheum. (2003) 48:1500-1503.
3. VAN VOLLENHOVEN RF, BRANNEMARK S, KLARESKOG L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann. Rheum. Dis. (2004) 63:426-430.
4. VAN VOLLENHOVEN R, HARJU A, BRANNEMARK S, KLARESKOG L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann. Rheum. Dis. (2003) 62:1195-1198.
5. SMOLEN J, VAN DER HEIJDE D, EMERY P et al.: Infliximab inhibits radiographic joint damage in patients with early rheumatoid arthritis regardless of clinical response after 54-week treatment. Ann. Rheum. Dis. (2004) 63(Suppl.I):260.
6. SZEANECZ Z, KOCH AE: Chemokines and angiogenesis. Arthritis Res. (2001) 13:202-208.
7. PANAYI GS, CORRIGALL VM, PITZALIS C: Pathogenesis of rheumatoid arthritis. Role of T cells and other beasts. Rhuem. Dis. Clin. N. America (2001) 27:317.
8. ZHAN Z, BRIDGES SL Jr: Pathogenesis of rheumatoid arthritis. Role of B cells. Rheum. Dis. Clin. N. America (2001) 27:335-353.
9. YAMANISHI Y, FIRESTEIN CS: Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. N. America (2001) 27:355-371.
10. KOCH AE: Angiogenesis Implications for Rheumatoid Arthritis. Arthritis Rheum. (1998) 41:951-962.
11. KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of Rheumatoid Arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. NEJM (2003), 349:1907-1915.
12. WEINBLATT M, SCHIFF M, GOLDMAN M et al.: A pilot, multi-center, randomized, double-blind, placebo controlled trial ofa co-stimulatory blocker CTLA4Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. Arthritis Rheum. (2002) 46(Suppl.):S203 (Abstract 463).
13. DE VITA S, ZAJA F, SACCO S et al.: Effcacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum. (2002) 46:2029.
14. TAKEMURA S, KLIMIUK PA, BRAUN A et al.: T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. (2001) 167:4710-4718.
15. EDWARDS JCW, CAMBRIDGE G: Sustained improvement in RA following a protocol designed to deplete B lymphocytes. Rheumatology (2001) 40:205-211.
16. LEANDRO MD, EDWARDS JCW, CAMBRIDGE G: Clinical outcome in 22 patients with RA treated with B lymphocyte depletion. Ann. Rheum. Dis. (2002) 61:883-888.
17. EDWARDS JCW, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy and safety of Rituximab, a B cell targeted chimeric monoclonal antibody: a placebo RCT in patients with RA. Arthritis Rheum. (2002) 46(Suppl.9):S197.
18. TUSCANO JM: Successful treatment of infliximab-refractor rheumatoid arthritis with Rixuximab. Presented at the American College of Rheumatology, Atlanta, USA. October (2002) (Late breaking abstract).
19. EMERY P, SZCZEPANSKI L, SZECHINSKI J et al.: Sustained efficacy at 48 weeks after single treatment course of Rituximab in patients with rheumatoid arthritis. Arthritis Rhuem. (2003) 48(9):5439 (Abstract 1095).
20. SZECHINSKI J, SZCZEPANSKI L, FILIPOWICZ-SOSNOWSKA A et al.: Treatment of RA with Rituximab leads to selective peripheral B-cell depletion with minimal effect on immunoglobulins. Ann. Rheum. Dis. (2003) 62 Thu 0205 (Abstract).
21. CAMBRIDGE G, LEANDRO MJ, Edwards JCW et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rhuem. Dis. (2003) 48(8):2146-2154.
22. SZCZEPANSKI L, SZECHINSKI J, FILIPOWICZ-SOSNOWSKA A et al.: Infusions of Rituximab in patients with rheumatoid arthritis are well tolerated. Ann. Rheum. Dis. (2003) 62 thu 0206 (Abstract).
23. SZCZEPANSKI L, SZECHINSKI J, FILIPOWICZ-SOSNOWSKA A et al.: Safety data from 48 weeks follow-up of a randomized controlled trial of rituximab in patients with rheumatoid arthritis. Arthritis Rhuem. (2003) 48(Suppl.):S121 (Abstract 204).
24. CHOY EHS, ISENBERG DA, GARROOD T et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose escalation trial. Arthritis Rheum. (2002) 46:3143-3150.
25. MAINI RN, TAYLOR PC, PAVELKA K et al.: Efficacy of IL-6 Receptor Antagonist MRA in Rheumatoid Arthritis Patients with an Incomplete Response to Methotrexate (CHARISMA). Arthritis Rheum. (2003) 48(Suppl.):S652 (Abstract 1704).
26. NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of Rheumatoid Arthritis with Humanized Anti-interleukin-6 receptor antibody. Arthritis Rheum. (2004) 50:1761-1769.